Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.79
AMEX:PLX's Cash-to-Debt is ranked lower than
81% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. AMEX:PLX: 0.79 )
Ranked among companies with meaningful Cash-to-Debt only.
AMEX:PLX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41  Med: No Debt Max: No Debt
Current: 0.79
0.41
No Debt
Equity-to-Asset -0.61
AMEX:PLX's Equity-to-Asset is ranked lower than
96% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMEX:PLX: -0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
AMEX:PLX' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.15  Med: -0.14 Max: 0.8
Current: -0.61
-1.15
0.8
Debt-to-Equity -1.32
AMEX:PLX's Debt-to-Equity is ranked lower than
99.99% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. AMEX:PLX: -1.32 )
Ranked among companies with meaningful Debt-to-Equity only.
AMEX:PLX' s Debt-to-Equity Range Over the Past 10 Years
Min: -9.07  Med: -1.11 Max: 27.25
Current: -1.32
-9.07
27.25
Debt-to-EBITDA -2.19
AMEX:PLX's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. AMEX:PLX: -2.19 )
Ranked among companies with meaningful Debt-to-EBITDA only.
AMEX:PLX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.4  Med: -2.67 Max: -0.71
Current: -2.19
-3.4
-0.71
Piotroski F-Score: 5
Altman Z-Score: 0.03
Beneish M-Score: -4.59
WACC vs ROIC
14.70%
398.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -194.37
AMEX:PLX's Operating Margin % is ranked lower than
58% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. AMEX:PLX: -194.37 )
Ranked among companies with meaningful Operating Margin % only.
AMEX:PLX' s Operating Margin % Range Over the Past 10 Years
Min: -8239.43  Med: -621.79 Max: -35.36
Current: -194.37
-8239.43
-35.36
Net Margin % -169.94
AMEX:PLX's Net Margin % is ranked lower than
69% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. AMEX:PLX: -169.94 )
Ranked among companies with meaningful Net Margin % only.
AMEX:PLX' s Net Margin % Range Over the Past 10 Years
Min: -8103.09  Med: -439.89 Max: 1329.9
Current: -169.94
-8103.09
1329.9
ROA % -54.01
AMEX:PLX's ROA % is ranked lower than
89% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. AMEX:PLX: -54.01 )
Ranked among companies with meaningful ROA % only.
AMEX:PLX' s ROA % Range Over the Past 10 Years
Min: -110.42  Med: -34.11 Max: 66.1
Current: -54.01
-110.42
66.1
ROC (Joel Greenblatt) % -324.05
AMEX:PLX's ROC (Joel Greenblatt) % is ranked lower than
60% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. AMEX:PLX: -324.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMEX:PLX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -922.53  Med: -235.93 Max: -67
Current: -324.05
-922.53
-67
3-Year Revenue Growth Rate 57.00
AMEX:PLX's 3-Year Revenue Growth Rate is ranked higher than
88% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. AMEX:PLX: 57.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMEX:PLX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 323.2
Current: 57
0
323.2
3-Year EBITDA Growth Rate -27.40
AMEX:PLX's 3-Year EBITDA Growth Rate is ranked lower than
81% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. AMEX:PLX: -27.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMEX:PLX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -83  Med: 9.9 Max: 53.3
Current: -27.4
-83
53.3
3-Year EPS without NRI Growth Rate -21.80
AMEX:PLX's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. AMEX:PLX: -21.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMEX:PLX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.1 Max: 49.3
Current: -21.8
0
49.3
GuruFocus has detected 1 Warning Sign with Protalix BioTherapeutics Inc AMEX:PLX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMEX:PLX's 30-Y Financials

Financials (Next Earnings Date: 2018-08-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

PLX Guru Trades in Q2 2017

Jim Simons 2,300,800 sh (+19.37%)
» More
Q3 2017

PLX Guru Trades in Q3 2017

Jim Simons 2,101,300 sh (-8.67%)
» More
Q4 2017

PLX Guru Trades in Q4 2017

Jim Simons 1,993,500 sh (-5.13%)
» More
Q1 2018

PLX Guru Trades in Q1 2018

Jim Simons 2,309,500 sh (+15.85%)
» More
» Details

Insider Trades

Latest Guru Trades with AMEX:PLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:XCNQ:SUN, TSXV:DMA, OSTO:SENZA, LSE:IMM, TSX:HBP, ASX:PYC, NAS:BCLI, LSE:SCLP, ROCO:6580, NAS:VTVT, TPE:1762, ASX:BOT, OTCPK:BCDA, TSE:2342, NAS:ZSAN, LSE:ABZA, OTCPK:IPIX, XKRX:216400, TSXV:COV, NSE:ZOTA » details
Traded in other countries:PBD.Germany, PLX.Israel,
Headquarter Location:Israel
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system, or ProCellEx.

Protalix BioTherapeutics Inc is a part of the healthcare domain. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa, for the treatment of Gaucher disease. Its products also treat diseases like Fabry disease and cystic fibrosis. Its pipeline products include Alidornase Alfa, Pegunigalsidase Alfa, and Oprx-106.

Top Ranked Articles about Protalix BioTherapeutics Inc

Research Report Identifies Comtech Telecommunications, Protalix BioTherapeutics, Kraton, ABB, Cheniere Energy Partners LP, and Heidrick & Struggles International with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration
Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium™ 2018
Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission
Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis
Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference
Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union
Protalix BioTherapeutics to Hold Third Quarter 2017 Financial Results and Corporate Update Conference Call on November 8, 2017

Ratios

vs
industry
vs
history
PS Ratio 3.17
PLX's PS Ratio is ranked higher than
70% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. PLX: 3.17 )
Ranked among companies with meaningful PS Ratio only.
PLX' s PS Ratio Range Over the Past 10 Years
Min: 3.02  Med: 39.2 Max: 1618
Current: 3.17
3.02
1618
EV-to-EBIT -2.93
PLX's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. PLX: -2.93 )
Ranked among companies with meaningful EV-to-EBIT only.
PLX' s EV-to-EBIT Range Over the Past 10 Years
Min: -51  Med: -10.5 Max: -1.1
Current: -2.93
-51
-1.1
EV-to-EBITDA -3.15
PLX's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. PLX: -3.15 )
Ranked among companies with meaningful EV-to-EBITDA only.
PLX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -81.6  Med: -11.6 Max: -1.2
Current: -3.15
-81.6
-1.2
EV-to-Revenue 3.58
PLX's EV-to-Revenue is ranked higher than
72% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. PLX: 3.58 )
Ranked among companies with meaningful EV-to-Revenue only.
PLX' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.4  Med: 37.2 Max: 1439
Current: 3.58
3.4
1439
Current Ratio 2.59
PLX's Current Ratio is ranked lower than
64% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. PLX: 2.59 )
Ranked among companies with meaningful Current Ratio only.
PLX' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 4.39 Max: 91.65
Current: 2.59
1.02
91.65
Quick Ratio 2.26
PLX's Quick Ratio is ranked lower than
65% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. PLX: 2.26 )
Ranked among companies with meaningful Quick Ratio only.
PLX' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 4.39 Max: 91.65
Current: 2.26
0.96
91.65
Days Inventory 165.79
PLX's Days Inventory is ranked lower than
64% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. PLX: 165.79 )
Ranked among companies with meaningful Days Inventory only.
PLX' s Days Inventory Range Over the Past 10 Years
Min: 24.15  Med: 175.68 Max: 3304.7
Current: 165.79
24.15
3304.7
Days Sales Outstanding 83.04
PLX's Days Sales Outstanding is ranked higher than
76% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. PLX: 83.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
PLX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.95  Med: 100.81 Max: 2016.91
Current: 83.04
14.95
2016.91
Days Payable 110.68
PLX's Days Payable is ranked higher than
80% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. PLX: 110.68 )
Ranked among companies with meaningful Days Payable only.
PLX' s Days Payable Range Over the Past 10 Years
Min: 110.68  Med: 539.55 Max: 2222.44
Current: 110.68
110.68
2222.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.40
PLX's 3-Year Average Share Buyback Ratio is ranked lower than
57% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. PLX: -15.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PLX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -539.3  Med: -5 Max: 14
Current: -15.4
-539.3
14

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.08
PLX's Price-to-Median-PS-Value is ranked higher than
95% of the 614 Companies
in the Global Biotechnology industry.

( Industry Median: 1.00 vs. PLX: 0.08 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PLX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.57 Max: 33.1
Current: 0.08
0.01
33.1
Earnings Yield (Greenblatt) % -34.27
PLX's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. PLX: -34.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PLX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -87.6  Med: -9.6 Max: -2
Current: -34.27
-87.6
-2

More Statistics

Revenue (TTM) (Mil) $20.91
EPS (TTM) $ -0.31
Beta2.01
Volatility61.66%
52-Week Range $0.39 - 0.92
Shares Outstanding (Mil)145.57

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 34 60 92
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.13 0.07 0.43
EPS without NRI ($) -0.13 0.07 0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}